2 Information about pembrolizumab

2 Information about pembrolizumab

Marketing authorisation indication

Pembrolizumab (Keytruda, Merck Sharp & Dohme) has a marketing authorisation as monotherapy for 'the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection'.

Dosage in the marketing authorisation

200 mg every 3 weeks by intravenous infusion for 1 year.


£2,630.00 per 100‑mg vial (excluding VAT; British national formulary [BNF] online [accessed September 2018]).

The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)